SCHEDULE 13G/A 0001172661-25-004831 0001856083 XXXXXXXX LIVE 3 Common Stock, $0.0001 par value per share 12/31/2025 0001393434 Ocular Therapeutix, Inc 67576A100 15 Crosby Drive Bedford MA 01730 Rule 13d-1(c) Deep Track Capital, LP b DE 0.00 0.00 0.00 9234132.00 9234132.00 N 4.31 IA OO Deep Track Biotechnology Master Fund, Ltd. b E9 0.00 9234132.00 0.00 9234132.00 9234132.00 N 4.31 CO David Kroin b X1 0.00 9234132.00 0.00 9234132.00 9234132.00 N 4.31 HC IN Ocular Therapeutix, Inc 15 Crosby Drive, Bedford, MA 01730 (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (i) Delaware (ii) Cayman Islands (iii) United States Y 9,234,132 4.31% 0 0 0 9,234,132 N Y Y N Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 214,211,190 shares, calculated using 213,047,472 Common Stock outstanding as of October 31, 2025, according to the issuer's 10-Q filed with the SEC on November 4, 2025 and 1,163,718 Common Stock that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 1,163,718 Pre-Funded Warrants exercisable to common shares, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Pre-Funded Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 10, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Capital, LP /s/ David Kroin 02/10/2026 Deep Track Biotechnology Master Fund, Ltd. /s/ David Kroin 02/10/2026 David Kroin /s/ David Kroin 02/10/2026